BR112022022634A2 - Inibidores de atr para o tratamento de câncer - Google Patents
Inibidores de atr para o tratamento de câncerInfo
- Publication number
- BR112022022634A2 BR112022022634A2 BR112022022634A BR112022022634A BR112022022634A2 BR 112022022634 A2 BR112022022634 A2 BR 112022022634A2 BR 112022022634 A BR112022022634 A BR 112022022634A BR 112022022634 A BR112022022634 A BR 112022022634A BR 112022022634 A2 BR112022022634 A2 BR 112022022634A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treatment
- atr inhibitors
- atr
- inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INIBIDORES DE ATR PARA O TRATAMENTO DE CÂNCER. A presente invenção refere-se ao uso de um inibidor de ATR, preferencialmente em combinação com um taxano, para o tratamento de câncer em um subconjunto particular de pacientes que receberam previamente imunoterapia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022730P | 2020-05-11 | 2020-05-11 | |
| US202163166291P | 2021-03-26 | 2021-03-26 | |
| PCT/EP2021/062307 WO2021228758A1 (en) | 2020-05-11 | 2021-05-10 | Atr inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022634A2 true BR112022022634A2 (pt) | 2022-12-13 |
Family
ID=75904929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022634A BR112022022634A2 (pt) | 2020-05-11 | 2021-05-10 | Inibidores de atr para o tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230346791A1 (pt) |
| EP (1) | EP4149455A1 (pt) |
| JP (1) | JP2023524872A (pt) |
| KR (1) | KR20230009481A (pt) |
| CN (1) | CN115515577A (pt) |
| AU (1) | AU2021269764A1 (pt) |
| BR (1) | BR112022022634A2 (pt) |
| CA (1) | CA3181382A1 (pt) |
| IL (1) | IL297842A (pt) |
| MX (1) | MX2022014104A (pt) |
| TW (1) | TW202207941A (pt) |
| WO (1) | WO2021228758A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022200557A1 (en) * | 2021-03-26 | 2022-09-29 | Astrazeneca Ab | Combination treatments for melanoma |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| JP2022502399A (ja) * | 2018-09-26 | 2022-01-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ |
-
2021
- 2021-05-10 KR KR1020227043328A patent/KR20230009481A/ko unknown
- 2021-05-10 US US17/998,275 patent/US20230346791A1/en active Pending
- 2021-05-10 IL IL297842A patent/IL297842A/en unknown
- 2021-05-10 JP JP2022568542A patent/JP2023524872A/ja active Pending
- 2021-05-10 BR BR112022022634A patent/BR112022022634A2/pt not_active Application Discontinuation
- 2021-05-10 MX MX2022014104A patent/MX2022014104A/es unknown
- 2021-05-10 CN CN202180033797.3A patent/CN115515577A/zh active Pending
- 2021-05-10 CA CA3181382A patent/CA3181382A1/en active Pending
- 2021-05-10 WO PCT/EP2021/062307 patent/WO2021228758A1/en active Application Filing
- 2021-05-10 AU AU2021269764A patent/AU2021269764A1/en active Pending
- 2021-05-10 EP EP21725127.1A patent/EP4149455A1/en active Pending
- 2021-05-11 TW TW110116938A patent/TW202207941A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524872A (ja) | 2023-06-13 |
| IL297842A (en) | 2023-01-01 |
| KR20230009481A (ko) | 2023-01-17 |
| CN115515577A (zh) | 2022-12-23 |
| MX2022014104A (es) | 2022-12-08 |
| CA3181382A1 (en) | 2021-11-18 |
| EP4149455A1 (en) | 2023-03-22 |
| AU2021269764A1 (en) | 2023-01-19 |
| TW202207941A (zh) | 2022-03-01 |
| US20230346791A1 (en) | 2023-11-02 |
| WO2021228758A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001551A1 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
| BR112019003914A2 (pt) | inibidores de processos metabólicos celulares | |
| BRPI0606542A2 (pt) | métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab | |
| BR112023014751A2 (pt) | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| GB201114051D0 (en) | Compounds and their uses | |
| BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
| BR112018069976A2 (pt) | anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo. | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| BR112013026327A2 (pt) | inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| BR112022017724A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
| ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CL2022002410A1 (es) | Terapia combinada de inhibidores axl/mer y pd-1/pd-l1. | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |